Car-t cell therapy for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or not responded to previous treatments.
- You have already tried at least three different types of treatment.
- You have not been treated with a type of therapy that targets GPRC5D or CD19 proteins.
- You do not have active hepatitis B, hepatitis C, or HIV infections.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.